Your session is about to expire
← Back to Search
ADG116 + Immunotherapy for Cancer
Study Summary
This trial is testing a new cancer treatment that could be more effective than current options.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Part C : Dose escalation of ADG116 combined with ADG106
- Group 2: Part B : Dose escalation of ADG116 combined with anti PD1 drug
- Group 3: Part A : Dose escalation of ADG116 monotherapy
Frequently Asked Questions
Has ADG116 obtained clearance from the Food and Drug Administration?
"ADG116's safety profile is rated 1, as it has not yet been subject to extensive clinical trials. Consequently, the available data regarding efficacy and safety are limited."
How many research participants have been enlisted to participate in this project?
"Affirmative. Clinicaltrials.gov indicates that this medical trial, which was initially advertised on 23rd September 2020, is actively recruiting individuals for the study. 204 patients must be sourced from a single site to complete the research project."
Is this experiment currently open to recruitment?
"Correct. According to clinicaltrials.gov, this trial is seeking participants and was initially posted on September 23rd 2020 before its most recent update on January 26th 2022. The research requires 204 volunteers from 1 medical site."
Share this study with friends
Copy Link
Messenger